Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Accounts Payables: 2014-2025

Historic Accounts Payables for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $646,000.

  • CytomX Therapeutics' Accounts Payables fell 54.57% to $646,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $646,000, marking a year-over-year decrease of 54.57%. This contributed to the annual value of $1.1 million for FY2024, which is 25.38% down from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Accounts Payables is $646,000, which was up 184.58% from $227,000 recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Accounts Payables ranged from a high of $5.2 million in Q3 2022 and a low of $227,000 during Q2 2025.
  • For the 3-year period, CytomX Therapeutics' Accounts Payables averaged around $1.1 million, with its median value being $1.1 million (2024).
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 241.42% in 2022, then slumped by 85.95% in 2025.
  • CytomX Therapeutics' Accounts Payables (Quarterly) stood at $2.8 million in 2021, then decreased by 0.32% to $2.8 million in 2022, then plummeted by 48.10% to $1.5 million in 2023, then dropped by 25.38% to $1.1 million in 2024, then plummeted by 54.57% to $646,000 in 2025.
  • Its last three reported values are $646,000 in Q3 2025, $227,000 for Q2 2025, and $276,000 during Q1 2025.